Posted on 16/03/2010 in Scientific Sigma-Aldrich is to sell around 100 small molecule compounds developed by Pfizer in a move which will aid the research community's studies into biological systems.
Under the terms of the agreement, the compounds are to be sold to life science researchers for the purposes of target characterisation, assay development and in vivo animal model applications, with many molecules being made available for the first time.
This selection will initially include compounds such as atorvastatin, sildenafil and celecoxib, with Sigma-Aldrich planning to add further compounds on a regular basis.
Dr David Smoller, president of Sigma Life Science's biotech research business unit, said this would allow the science community to access "interesting and research-relevant bioactive small molecules".
He added: "This multi-compound deal not only enriches our extensive portfolio of products ? but provides valuable resources that will enable our customers to modulate their protein targets."
Last week, the science firm licensed a new organic polymer technology developed by the Australian Commonwealth Scientific and Industrial Research Organization, which is designed to allow better control over polymer weight and structure.Other news stories from 16/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
